Literature DB >> 32540921

Blood Glucose Control During Lockdown for COVID-19: CGM Metrics in Italian Adults With Type 1 Diabetes.

Brunella Capaldo1, Giovanni Annuzzi2, Annalisa Creanza1, Clemente Giglio1, Raffaele De Angelis1, Roberta Lupoli1, Maria Masulli1, Gabriele Riccardi1, Angela Albarosa Rivellese1, Lutgarda Bozzetto1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32540921      PMCID: PMC7372051          DOI: 10.2337/dc20-1127

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
To prevent the spread of COVID-19, lockdown was imposed in many countries with rigid restrictions on all outdoor activities, also limiting attendance at diabetes clinics. In patients with diabetes, lockdown implies lifestyle changes related to physical activity, stress, and nutrition that are likely to adversely affect glycemic control (1). Conversely, during lockdown, individuals with type 1 diabetes (T1D) are to be expected to have a more regular lifestyle, more closely respecting time schedules and insulin administration timing. We evaluated the impact of lockdown on glucose control in 207 Italian adults with T1D attending the Diabetes Outpatient Clinic of the Federico II University Hospital, Naples: 96 females/111 males, mean ± SD age 38.4 ± 12.7 years, 104 on multiple daily insulin injections (MDI), and 103 on insulin pump (continuous subcutaneous insulin infusion [CSII]). Inclusion criteria were continuous glucose monitoring (CGM) for at least 6 months, including a 2-week period with CGM use >70% before (January–February) and during (March–April 2020) lockdown, while maintaining the same device: FreeStyle (n = 130), Guardian 3 (n = 47), Dexcom G6 (n = 18), and Eversense (n = 12). Each participant gave informed consent for the use of her or his data. No participant reported COVID-19 infection during the study. Time in target range (TIR) (3.9–10.0 mmol/L), time above target range (TAR) (>10.0 mmol/L and >13.9 mmol/L), and time below target range (TBR) (<3.9 mmol/L and <3.0 mmol/L) expressed as percentage of all CGM readings, mean glucose, and glycemic variability (coefficient of variation [CV%]) were analyzed (2). An online questionnaire provided data on physical activity, dietary habits, and sleeping pattern. The primary outcome was change in TIR (%) from prelockdown to lockdown period. Secondary end points were changes in TAR, TBR, and CV%. Results are shown in Tables 1 and 2. During lockdown, TIR increased significantly (P = 0.002) in the whole cohort and subgroups of sex, age (<35 or ≥35 years), and insulin regimen (MDI or CSII). Glycemic variability (CV%) decreased significantly (P = 0.001), with the change being more relevant in relation to lower age (P < 0.001 vs. ≥35 years), male sex (P < 0.001 vs. female), and MDI use (P < 0.001 vs. CSII). This improvement was due to reduction of hypoglycemia <3.0 mmol/L (P < 0.001)—more evident in MDI participants (P = 0.025 vs. CSII)—and hyperglycemia >13.9 mmol/L (P = 0.052). During lockdown, participants reduced their physical activity, had a more regular meal pattern with a higher food intake and more frequent snacking, and went to bed later and woke up later. Participants who increased sleep duration (n = 63) showed a greater, although not statistically significant, increase in TIR than those who decreased it (n = 53) (4.1 ± 13.2% vs. 0.17 ± 11.5%, P = 0.088). Changes in physical activity during lockdown were significantly positively associated with changes in glucose CV% (Pearson correlation, r = 0.155, P = 0.038) but not with changes in TIR (r = 0.019, P = 0.800).
Table 1

CGM metrics before and during lockdown in the study participants

CGM metrics (n = 207)Before lockdownDuring lockdownP value*
CGM use (%)91.2 ± 9.190.1 ± 8.60.081
Mean glucose (mmol/L)9.6 ± 2.09.5 ± 1.90.165
Estimated HbA1c (%)7.7 ± 1.37.6 ± 1.10.098
Estimated HbA1c (mmol/mol)60 ± 1059 ± 90.098
TAR (%)
 >180 mg/dL (10.0 mmol/L)26.8 ± 11.226.3 ± 11.20.414
 >250 mg/dL (13.9 mmol/L)14.7 ± 15.313.2 ± 13.70.052
TIR (%)55.6 ± 17.658.2 ± 18.10.002
TBR (%)
 <70 mg/dL (3.9 mmol/L)2.95 ± 3.052.71 ± 3.080.192
 <54 mg/dL (3.0 mmol/L)1.42 ± 2.390.58 ± 1.17<0.001
Glycemic variability (CV%)35.9 ± 7.034.7 ± 6.30.001

Data are expressed as mean ± SD.

Paired sample t test.

Table 2

Questionnaire-derived lifestyle data before and during lockdown in the study participants

Lifestyle changes compared with prelockdown (n = 182)MoreLessSameP value§
Total physical activity#25 (14)127 (70)30 (16)<0.001
Food amount76 (42)16 (9)90 (49)<0.001
Regularity of mealtimes47 (26)40 (22)95 (52)<0.001
Number of snacks46 (25)16 (9)120 (66)<0.001
Sleep duration63 (35)53 (29)66 (36)0.318
LaterEarlierSame
Bedtime105 (57)11 (6)66 (36)<0.001
Waking time96 (53)32 (17)54 (30)<0.001

Data are expressed as number of participants (%).

χ2 test.

Score based on type and frequency of physical activity.

CGM metrics before and during lockdown in the study participants Data are expressed as mean ± SD. Paired sample t test. Questionnaire-derived lifestyle data before and during lockdown in the study participants Data are expressed as number of participants (%). χ2 test. Score based on type and frequency of physical activity. This study shows that during lockdown for COVID-19, patients with T1D had improved glucose control indicated by increased TIR, reduced glucose variability, and reduced hyperglycemia and severe hypoglycemia. These findings are somewhat unexpected considering that, because of home confinement, patients had no access to outpatient diabetes clinics—although interacting with their diabetes team by teleconsulting—and less opportunity to perform physical activities. We can hypothesize that the improved glucose control observed in our patients could result from a more regular lifestyle, including reproducible mealtimes and more time for self-care, as also supported by the increased TIR associated with increased sleep duration (3,4). The reduction in physical activity may have also played a role, considering the well-known difficulties to appropriately modulate carbohydrate intake and insulin doses in relation to exercise. In fact, in our study, the reduction in physical activity was associated with reduced glucose variability but unchanged TIR, in line with the evidence that physical activity, while exerting favorable effects on weight, cardiovascular fitness, lipid profile, and psychological well-being (5) in people with T1D, does not clearly associate with improved glycemic control. A strength of our study is that COVID-19 restrictions represented an unprecedented, hopefully unique condition in which to evaluate the effects of home confinement in a free-living T1D population. Moreover, CGM cloud platforms provide new metrics of glucose control including glycemic variability. A limitation is that lifestyle data were mainly qualitative. Moreover, the lack of a control group does not allow assignment of the observed changes to lockdown. However, because of the extraordinary condition patients were facing, these changes were very unlikely due to general trends or other unmeasured factors. In conclusion, in adults with T1D, glucose control improved during lockdown, highlighting the importance of a more stable rhythm of life, including more regular mealtimes. Lifestyle changes in patients with T1D should take into consideration not only diet and physical activity but also a more regular and less stressful life.
  5 in total

1.  Impact of Physical Activity on Glycemic Control and Prevalence of Cardiovascular Risk Factors in Adults With Type 1 Diabetes: A Cross-sectional Multicenter Study of 18,028 Patients.

Authors:  Barbara Bohn; Antje Herbst; Martin Pfeifer; Dietmar Krakow; Stefan Zimny; Florian Kopp; Andreas Melmer; Jürgen M Steinacker; Reinhard W Holl
Journal:  Diabetes Care       Date:  2015-05-26       Impact factor: 19.112

2.  Differences in the management of type 1 diabetes among adults under excellent control compared with those under poor control in the T1D Exchange Clinic Registry.

Authors:  Jill H Simmons; Vincent Chen; Kellee M Miller; Janet B McGill; Richard M Bergenstal; Robin S Goland; David M Harlan; Joseph F Largay; Elaine M Massaro; Roy W Beck
Journal:  Diabetes Care       Date:  2013-09-11       Impact factor: 19.112

Review 3.  Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.

Authors:  Tadej Battelino; Thomas Danne; Richard M Bergenstal; Stephanie A Amiel; Roy Beck; Torben Biester; Emanuele Bosi; Bruce A Buckingham; William T Cefalu; Kelly L Close; Claudio Cobelli; Eyal Dassau; J Hans DeVries; Kim C Donaghue; Klemen Dovc; Francis J Doyle; Satish Garg; George Grunberger; Simon Heller; Lutz Heinemann; Irl B Hirsch; Roman Hovorka; Weiping Jia; Olga Kordonouri; Boris Kovatchev; Aaron Kowalski; Lori Laffel; Brian Levine; Alexander Mayorov; Chantal Mathieu; Helen R Murphy; Revital Nimri; Kirsten Nørgaard; Christopher G Parkin; Eric Renard; David Rodbard; Banshi Saboo; Desmond Schatz; Keaton Stoner; Tatsuiko Urakami; Stuart A Weinzimer; Moshe Phillip
Journal:  Diabetes Care       Date:  2019-06-08       Impact factor: 19.112

4.  Short sleep duration measured by wrist actimetry is associated with deteriorated glycemic control in type 1 diabetes.

Authors:  Anne-Laure Borel; Jean-Louis Pépin; Laure Nasse; Jean-Philippe Baguet; Sophie Netter; Pierre-Yves Benhamou
Journal:  Diabetes Care       Date:  2013-05-28       Impact factor: 19.112

5.  Meal timing, meal frequency, and breakfast skipping in adult individuals with type 1 diabetes - associations with glycaemic control.

Authors:  Aila J Ahola; Stefan Mutter; Carol Forsblom; Valma Harjutsalo; Per-Henrik Groop
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  5 in total
  40 in total

Review 1.  The Impact of the SARS-CoV-2 Pandemic on Healthcare Provision in Italy to non-COVID Patients: a Systematic Review.

Authors:  Gianmarco Lugli; Matteo Maria Ottaviani; Annarita Botta; Guido Ascione; Alessandro Bruschi; Federico Cagnazzo; Lorenzo Zammarchi; Paola Romagnani; Tommaso Portaluri
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-01-01       Impact factor: 2.576

2.  Effect of the COVID-19 pandemic on glycemic control in Brazilian patients with type 2 diabetes.

Authors:  L R M Tannus; R M Zapelini; C A Cabizuca; R C Abi-Abib; A S M Matheus; P C Calassara; R Pozzan; R A Cobas
Journal:  Endocrine       Date:  2022-07-15       Impact factor: 3.925

Review 3.  Physical Activity during COVID-19 Lockdown in Italy: A Systematic Review.

Authors:  Luciana Zaccagni; Stefania Toselli; Davide Barbieri
Journal:  Int J Environ Res Public Health       Date:  2021-06-13       Impact factor: 3.390

4.  Improvement in Mean CGM Glucose in Young People with Type 1 Diabetes During 1 Year of the COVID-19 Pandemic.

Authors:  Tara Kaushal; Liane Tinsley; Lisa K Volkening; Louise Ambler-Osborn; Lori Laffel
Journal:  Diabetes Technol Ther       Date:  2021-10-13       Impact factor: 6.118

5.  COVID-19 Precautionary Measures and Type 1 Diabetes Patients in Saudi Arabia.

Authors:  Abdullah Alguwaihes; Mohammed E Al-Sofiani; Ebtihal Alyusuf; Aeshah Almutairi; Eman Ibrahim; Sarah S Albunyan; Saad Alzahrani; Rana Hasanto; Anwar A Jammah
Journal:  Prim Care Diabetes       Date:  2021-07-15       Impact factor: 2.459

6.  Improved glycaemia during the Covid-19 pandemic lockdown is sustained post-lockdown and during the "Eat Out to Help Out" Government Scheme, in adults with Type 1 diabetes in the United Kingdom.

Authors:  Parizad Avari; Rebecca Unsworth; Siân Rilstone; Chukwuma Uduku; Karen M Logan; Neil E Hill; Ian F Godsland; Monika Reddy; Nick Oliver
Journal:  PLoS One       Date:  2021-07-20       Impact factor: 3.240

Review 7.  COVID-19 and diabetes mellitus: from pathophysiology to clinical management.

Authors:  Soo Lim; Jae Hyun Bae; Hyuk-Sang Kwon; Michael A Nauck
Journal:  Nat Rev Endocrinol       Date:  2020-11-13       Impact factor: 47.564

8.  Management of glucose profile throughout strict COVID-19 lockdown by patients with type 1 diabetes prone to hypoglycaemia using sensor-augmented pump.

Authors:  Clara Viñals; Alex Mesa; Daria Roca; Merce Vidal; Irene Pueyo; Ignacio Conget; Marga Giménez
Journal:  Acta Diabetol       Date:  2020-10-30       Impact factor: 4.280

Review 9.  Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID-19 global pandemic.

Authors:  E G Wilmot; A Lumb; P Hammond; H R Murphy; E Scott; F W Gibb; J Platts; P Choudhary
Journal:  Diabet Med       Date:  2020-11-16       Impact factor: 4.213

10.  Glucose control in diabetes during home confinement for the first pandemic wave of COVID-19: a meta-analysis of observational studies.

Authors:  Giovanni Antonio Silverii; Chiara Delli Poggi; Ilaria Dicembrini; Matteo Monami; Edoardo Mannucci
Journal:  Acta Diabetol       Date:  2021-06-22       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.